EMAIL THIS PAGE TO A FRIEND

Molecular therapy. Methods & clinical development

Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.


PMID 28603746

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a polyglutamine expansion in the huntingtin (HTT) protein. There is currently no cure for this disease, but recent studies suggest that RNAi to downregulate the expression of both normal and mutant HTT is a promising therapeutic approach. We previously developed a small hairpin RNA (shRNA), vectorized in an HIV-1-derived lentiviral vector (LV), that reduced pathology in an HD rodent model. Here, we modified this vector for preclinical development by using a tat-independent third-generation LV (pCCL) backbone and removing the original reporter genes. We demonstrate that this novel vector efficiently downregulated

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

V3640
Valpromide, ≥97% (NMR)
C8H17NO